The best way to distinguish between primary and secondary changes are studies in unaffected relatives of patients with BD around the typical age of onset, as such studies are free from confounding effects of medication and comorbid conditions. However, no true high-risk studies of hippocampal or amygdala volumes in BD exist. A study by Velakoulis et al, 18 primarily interested in schizophrenia, included patients with first-episode psychotic affective disorder (n = 34) and patients at ultra-high risk for affective psychosis (n = 13), based on either presence of psychotic symptoms or family history. A combined group of participants at ultra-high risk for psychosis, without distinguishing between risk for affective or other psychoses, had normal hippocampal and amygdala volumes.
Two studies focused on first-degree relatives of patients with BD past the average age of onset. Noga et al, 22 in a small study of 6 monozygotic twin pairs discordant for BD (average age 34.5 years, SD 10.5), found no volume changes of amygdala-hippocampus in unaffected or affected twins relative to control subjects. McDonald et al 9 studied 38 patients with psychotic BD, 52 of their unaffected first-degree relatives (average age 44 years, SD 15) and 54 comparison patients. None of these groups showed any changes in hippocampal volumes.
To test whether volumes of amygdala or hippocampus represent a biological vulnerability marker for BD, we performed an MRI volumetric study of mesiotemporal structures in young affected and unaffected relatives of patients with BD (high-risk design). We controlled for known confounders (comorbid conditions, medication, burden of illness) in the design of our study. If mesiotemporal volumes are an endophenotype for BD, then affected offspring should show the largest differences relative to control subjects, with intermediate volumes among unaffected patients. As most studies reported lack of hippocampal volume changes 21 and decreased amygdala volumes in young patients with BD, 20 we expected to find comparable hippocampal and decreased amygdala volumes both in affected and in unaffected offspring of patients with BD relative to control subjects.
Methods

Subjects
Families. The high-risk patients were considered at an increased risk for development of BD, because they came from multiplex families (more than one member affected with BD) and had one parent affected with primary mood disorder, whereas the other parent was unaffected. The participants were recruited according to methods described elsewhere. 23 Briefly, suitable families were identified through adult probands with BD I or II, who had participated in genetic studies and had been recruited from outpatient clinics at the Queen Elizabeth II Health Centre in Halifax. Each proband completed a SADS-L interview 24 conducted by 2 research psychiatrists blind to the identity of the person. Final DSM-IV diagnoses were decided in a blind consensus fashion by an independent panel of senior clinical researchers using all available clinical materials. Similar to previous studies, 23, 25 we included patients with family history of BD II. Patients with BD II were comparable in their clinical presentation to the BD I participants in that they experienced a low prevalence of comorbid conditions and an episodic course of illness. BD II probands differed from BD I participants only in severity of mania. Family studies using similarly narrow diagnoses generally found BD II to be a part of the same genetic spectrum as BD I. 26 Further, neuroimaging studies have generally shown lack of differences between patients with BD I and II. [27] [28] [29] [30] [31] [32] Both BD I and II patients have thus previously been recruited for studies of hippocampal or amygdala volumes. 7, 15 High-Risk Offspring. Depending on their age, offspring were interviewed by a child, adolescent, or adult psychiatrist using KSADS-PL 33 or SADS-L format. Diagnoses were made based on DSM-IV, 34 as well as research diagnostic criteria 35 in a blind consensus review, which included at least 2 additional research psychiatrists. As part of the high-risk study, offspring are reassessed annually or at any time symptoms develop. The high-risk unaffected group was comprised of 26 offspring with no lifetime history of psychiatric disorder. High-risk affected patients consisted of 20 offspring who met criteria for a lifetime diagnosis of mood disorder or, in one case, psychosis not otherwise specified. As the subject with psychosis not otherwise specified had a family history of BD I and no family history of schizophrenia, his presentation is likely an antecedent of BD. All high-risk affected patients were in remission at the time of scanning, as determined by clinical interview and full functioning at school or work and absence of depressive or manic syndrome (Clinical Global Impression-Severity of Illness score of 0 or 1). None of the participants had a history of closed head injury resulting in loss of consciousness; untreated active medical illness (for example, diabetes); identified learning disability or diagnosis of ADHD; substance-related disorder within the past 6 months; lifetime history of substance dependence; or history of neurological disease.
Offspring of Well Parents (Control Subjects).
Control subjects consisted of 31 offspring of well parents recruited from similar sociodemographic areas as the patients. They were interviewed by a child, adolescent, or adult psychiatrist in accordance with KSADS-PL or SADS-L format and deemed to be well on blind consensus review. The control subjects were selected to closely match high-risk subjects by age and sex. Exclusion criteria were the same as in the high-risk groups with the addition of a personal or family history of psychiatric disorders.
Prior to conducting the assessments, all interviewers underwent extensive training consisting of participation in interviews, interviews under supervision, and blind consensus diagnostic reviews.
After complete description of our study to the participants, written informed consent was obtained. Our study was approved by the Research Ethics Boards of IWK Health Center and Capital District Health Authority, Halifax, Nova Scotia.
MRI Methods
MRI Acquisition Parameters. All MRI acquisitions were performed with a 1.5 Tesla General Electric Signa scanner and a standard single-channel head coil. After a localizer scan, a T 1 -weighted spoiled gradient recalled scan was acquired with the following parameters: flip angle = 40 degrees, echo time = 5 ms, repetition time = 25 ms, field of view = 24 cm × 18 cm, matrix = 256 × 160 pixels, number of excitations = 1, no interslice gap, and 124 images with 1.5 mm slice thickness.
MRI Volumetry. Anatomical measurements were conducted using the AFNI software for Linux, 36 in a single batch. Prior to volumetric measurements, all scans were reoriented perpendicular to the bicomissural line.
Hippocampus. We measured the whole volume of the hippocampus. Manual segmentation of the hippocampus started with tracing on the sagittal plane with continuous visualization of the other 2 orthogonal planes. The hippocampus can be best differentiated from the amygdala by using the axial plane. Consequently, as the second step, the tracing continued on the axial plane. Final editing was performed on the coronal plane.
The rostral subregion of the hippocampus was defined by the amygdala superiorly, by the cerebrospinal fluid in the temporal horn of the lateral ventricle laterally, and by the white matter of the parahippocampal gyrus inferiorly. For the rostral subregion, the hippocampal digitations, the subiculum, the cornu ammonis, and the alveus were included in the quantification of the hippocampal volume, while the uncal recess of the temporal horn and the white matter of the parahippocampal gyrus were excluded from the measurement. Boundaries between the hippocampus and the amygdala were defined by the edges of the hippocampal digitations, the uncal recess of the temporal horn of the lateral ventricle, and the alveus if it was observable. The body of the hippocampus was delimited by the lateral ventricle or the caudally adjacent white matter laterally, and by the white matter of the parahippocampal gyrus inferiorly. The superomedial border of the hippocampal body was identified by the superior arm of the quadrigeminal cistern. The fimbria, cornu ammonis, the subiculum, the gyrus dentatus, and the alveus were included in the measurement of these regions. The tail of the hippocampus was delimited superolaterally by crux of the fornix or by the caudally adjacent lateral ventricle, and by the isthmus of the cingulate gyrus at the ventral limit. Its superior limit was defined by the presence of the pulvinar or the splenium of the corpus callosum on more caudally located slices. Medial limit was defined by the cerebro spinal fluid of the quadrigeminal cistern or the isthmus of the cingulate gyrus. Measurement of the tail included the subiculum, the main hippocampal formation, the fimbria, the gyrus dentatus, and the alveus. The crux of the fornix, the parahippocampal gyrus, the isthmus of the cingulate gyrus, and the splenium of the corpus callosum were all excluded from measurements ( Figure 1 ).
Amygdala. Three-dimensional manual segmentation of amygdala started on the sagittal plane with continuous visualization of the other 2 orthogonal planes. As the second step, the tracing continued on the axial plane, while final editing was performed on the coronal plane. The tracing was completed in a caudo-rostral direction. On caudal slices the amygdala was limited by the temporal horn of the lateral ventricle inferiorly, the fibres of the unicinate fasciculus, the putamen, and the globus pallidus superiorly, and by the optic tract medially. Proceeding in rostral direction, the lateral ventricle, separating the hippocampal formation and the amygdaloid complex, disappears and the hippocampus becomes adjacent to the amygdala inferiorly. When the hippocampal formation disappears, the amygdaloid complex becomes limited by the white matter of the temporal lobe inferiorly and laterally, by nerve fibres, such as the ansa penducularis, and the optic tract superiorly, and by the entorhinal cortex medially. The most rostral slice was the slice previous to the one where the amygdala disappeared or the slice where the uncinate fasciculus was no longer seen. To prevent overlap of the hippocampus and amygdala ROI, which are poorly separated on MRI scans, the volume of the amygdaloid complex was obtained by subtracting the volume of the hippocampal formation from the volume of the hippocampal-amygdaloid complex (Figure 1 ).
Segmentations of both the hippocampus and the amygdala were performed by one investigator blinded to the diagnosis and group assignment of particpants. The intraclass correlation coefficients, established by tracing 10 scans by 2 independent raters, were r = 0.91 and r = 0.94 for the left and right hippocampus and r = 0.88 and r = 0.80 for the left and right amygdala (interrater reliability). Intraclass correlation coefficient for 10 randomly selected scans of our study subjects measured twice by the same rater were r = 0.95 and r = 0.98 for the left and right hippocampus and r = 0.88 and r = 0.94 for the left and right amygdala, respectively (intrarater reliability).
Grey matter volumes were obtained by automated segmentation in FMRIB software library. 37
Statistical Analyses
Statistical analyses were completed using the BMDP (Biomedical Package; Statistical Solutions, Saugus, MA) statistical software. We performed repeated measures analysis of variance separately with the amygdala and the hippocampus as the dependent variables, side (left, right hemisphere) as the repeated measure, and status (affected, unaffected, control subjects) as the grouping variable.
To compare grey matter volumes between affected and unaffected high-risk participants, and control subjects, we used one-way ANOVA. Categorical demographic variables (sex, handedness) were compared using Pearson's chi-square test. To look for association between age, intracranial volumes, and amygdala and hippocampus volumes, we used one-way analysis of covariance, (module 1V in BMDP statistical software [Biomedical Package; Statistical Solutions, Saugus, MA]).
We report nominal P values. In case of nominally significant results of analysis of variance, we corrected for our 2 main hypotheses (comparisons of hippocampal and amygdala volumes among groups).
Power analyses were performed using Statistica 6.0, software (StatSoft, Tulsa, OK). We carried out an a priori power analysis for one-way analysis of variance with 3 groups of participants, to calculate number of subjects needed to have sufficient power to detect effect sizes similar to those found in previous positive studies (ES = 0.6 6 to 0.9 8 for amygdala and ES = 0.9 10 for hippocampal volume decreases in pediatric or adolescent patients with BD) as statistically significant. We also carried out a post hoc power analysis for one-way ANOVA with 3 groups and an average of 25 subjects (77/3) in each group, to be able to estimate the smallest effect size detectable as statistically significant in our study. To compare our results to those of previous positive studies, we calculated Cohen's d effect size according to the formula Cohen's = M1-M2 s pooled d where s pooled = s1 + s2 2 2 2 For comparisons of 3 groups (affected and unaffected participants, and control subjects), we calculated the root mean square standardized effect size. The root-mean-square standardized effect size is calculated as the square root of the sum of squared standardized effects divided by the number of degrees of freedom for the effect.
Results
Demographics
Twenty-six unaffected familial, 20 affected familial, and 31 control subjects participated in our study. There were no differences in proportion of women, age, laterality or in grey matter volumes between the groups (Table 1) .
Hippocampal Volumes. There were no differences between affected and unaffected high-risk participants, and control subjects in hippocampal volumes (F = 1.83, df = 2,74, P = 0.17, ES = 0.27). The left hippocampus was significantly smaller than the right hippocampus (F = 26.38, df = 1,74, P < 0.001) in all groups (no interaction of group by side [F = 1.75, df = 2,74, P = 0.18]). The results of these analyses remained the same when covarying for overall grey matter volume. In exploratory analyses, excluding the medicated patients did not change the results. Age was not associated with hippocampal volumes. Hippocampal volumes were comparable between subjects with family history of BD I, compared with subjects with family history of BD II (t = 1.77, df = 44, P = 0.08, ES = 0.60), or between subjects with, relative to subjects without family history of psychotic symptoms during mood episodes (t = 0.73, df = 43, P = 0.47, ES = 0.22).
Amygdala Volumes. There were no differences between affected and unaffected high-risk participants, and control subjects in amygdala volumes (F = 1.82, df = 2,74, P = 0.17, ES = 0.30). The left amygdala was significantly larger than the right amygdala (F = 11.05, df = 1,74, P = 0.001) in all groups (no interaction of group by laterality [F = 0.32, df = 2,74, P = 0.72]). The results of these analyses remained the same when covarying for overall grey matter volume. In exploratory analyses, excluding the medicated patients did not change the results. Age was not associated with amygdala volumes. Amygdala volumes were comparable between subjects with family history of bipolar I, compared with subjects with family history of bipolar II disorders (t = 0.31, df = 44, P = 0.76, ES = 0.11) or between subjects with, relative to subjects without family history of psychotic symptoms during mood episodes (t = 0.11, df = 43, P = 0.91, ES = 0.03).
To ensure 90% statistical power to detect an effect size of 0.6 (the lowest effect size in previous positive study of mesiotemporal volumes decrease in pediatric or adolescent bipolar patients 6 ) at an alpha of 0.05, we would need 19 participants per group. With 25 participants in each of the 3 groups (77/3), we had 88.3% power to detect effect size of 0.5 as statistically significant.
Discussion
We found no changes in amygdala or hippocampal volumes in either affected or unaffected relatives of patients with BD when compared with control subjects without personal or family history of mood disorders. With 77 subjects, this is one of the largest MRI volumetric studies of amygdala and hippocampal volumes in patients with BD. Our study was sufficiently powered to detect effect sizes smaller than those reported in previous positive studies of amygdala or hippocampal volumes in patients with BD. The actual effect sizes for mesiotemporal ROI volume differences among groups found in this study, were small (ES = 0.3 and 0.27 for amygdala and hippocampus, respectively) and markedly lower than those found in previous positive studies reporting decreased amygdala (ES = 0.6 6 to 0.9 8 ) or hippocampal (ES = 0.9 10 ) volumes in young patients with BD. If there are biologically meaningful differences in subjects at genetic risk for BD relative to control subjects, based on our study, these appear to be only of less than one-third to one-half the extent of changes previously reported in patients with established illness. Further, we observed no pattern of changes consistent with plausible biological explanations. We expected to find the greatest differences between patients and control participants, with unaffected relatives showing intermediate values (affected, unaffected, control pattern), which was not the case for any of the ROI. Based on all of these arguments, it is thus unlikely that this is a false-negative study.
Similar to our results, all 3 previous MRI studies using manual tracing reported comparable amygdala and (or) hippocampal volumes in unaffected subjects at genetic or clinical risk for BD, relative to control participants. 9, 18, 22 Ladouceur et al 38 reported increased volumes of parahippocampal gyrus extending into hippocampus in absence of amygdala volume changes. These investigators used a different method of MRI data analysis (voxel-based morphometry) and the region of abnormal volume (parahippocampal gyrus extending to hippocampus) only partially overlapped with our ROIhippocampus. Neither of the 2 other voxel-based morphometry studies including unaffected relatives of patients with BD found hippocampal or amygdala volume changes. 39, 40 The lack of hippocampal and amygdala volume abnormalities in already affected relatives of patients with BD is also congruent with most studies in adult patients with BD. 7, [10] [11] [12] [13] 41 It is contrary to reports of decreased hippocampal 10 or amygdala [5] [6] [7] [8] volumes in children with BD or adolescents. This discrepancy is likely related to clinical heterogeneity and diagnostic controversies around childhood BD. The above-mentioned positive studies focused on patients with very early onset of BD, as early as 10 years of age or younger, a frequent rapid cycling, almost ubiquitous presence of comorbid conditions, predominantly ADHD, accompanied by exposure to psychostimulants. The cluster of mood lability, irritability, impulsivity, and attention deficits, which constitutes the phenotype of pediatric BD, as diagnosed in these studies, may not be continuous with adult classical bipolar illness, which presents with different behavioural symptoms 42 and a lack of hippocampal or amygdala volume changes. 20 The diagnostic controversies in children can be bypassed by the high-risk design, where offspring of parents with clear-cut primary mood disorders are followed. In a larger clinical, prospective investigation of offspring of parents with BD, including the scanned patients, the mean age of onset of BD among offspring was 15.7 years, the first episode in 81% of cases was depression, first manic episode occurred on average 3.3 years later, no subject manifested hypomanic or manic episode prior to age 12 years, and rates of ADHD among these patients were low-10%. 43 The participants in the above-mentioned positive studies of pediatric BD thus likely suffered from different conditions than patients included in our study.
Our findings are also contrary to reports of increased amygdala volumes in adults with BD. [14] [15] [16] [17] [18] However, most of these studies were confounded by effects of medication, which is known to increase mesiotemporal volumes. 21 We controlled for potential confounding effect of medication in the design of our study.
There are several limitations of our study. A prospective design would better allow us to capture changes in neuroanatomy related to neurodevelopment or burden of illness. Some of the affected patients suffered from unipolar depression, which is most typically the first manifestation of an illness, even in patients who later develop BD. 23, 44 About 70% of depressed first-degree relatives of bipolar probands are in fact bipolar, 45 and if we want to study early manifestations of BD, inclusion of these likely pseudo-unipolar subjects with family history of BD is thus inevitable. Aside from BD I subjects, we also included probands with conservatively defined BD II. There were no volumetric differences in mesiotemporal volumes between relatives of BD I and II patients. We thus feel that clinical heterogeneity did not affect our data, especially as we also excluded patients with other psychiatric comorbid conditions including alcohol or substance abuse and ADHD. We used manual tracing. To eliminate subjective bias, all tracings were done blindly. To ensure replicability, we used standard methods and tested interrater reliability, which was sufficient. In some cases more than one person per family was recruited. Typically, this would produce bias toward false-positive rather than false-negative results owing to spuriously lower variance estimates. As none of the volumetric findings were positive, we did not control for this.
A clear strength of our study is that the parents of the high-risk and control offspring were comprehensively assessed and that the offspring were followed and repeatedly prospectively studied. The stability and accuracy of the parent and offspring diagnoses is thus at the best possible clinical standard. In addition, the high-risk participants were largely psychotropic drug-naive and all subjects were free from other potential confounders such as prior substance use disorder or learning disabilities, and major neurological problems. Last but not least, this is the only true high-risk design study, that is, an investigation of affected as well as unaffected offspring of patients with BD around the age of illness onset. All of the previous studies including unaffected offspring, with exception of Ladouceur et al, 38 recruited patients past the average age of onset. This decreases the chance of finding biological risk factors, because the proportion of patients carrying biological risk factors among unaffected relatives of patients with BD decreases with age, as subjects carrying the biological susceptibility become affected. In other words, higher age among unaffected relatives of probands with BD acts as a selection bias toward subjects without biological risk factors.
Overall, our study adds to the growing literature showing that volumetric changes in the mesiotemporal structures including the hippocampus and the amygdala are not antecedent to onset of BD, and thus do not meet criteria for endophenotype. We also found lack of changes in already affected patients, when effects of medication exposure or comorbid conditions have been eliminated.
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Résumé : Volumes des amygdales et de l'hippocampe chez des parents de patients bipolaires : une étude dans une population à risque élevé
Objectif : Les troubles bipolaires (TB) ont une forte composante génétique et pourtant, aucun marqueur de vulnérabilité biologique aux TB n'a encore été identifié. Pour vérifier si les volumes des amygdales ou de 'hippocampe représentaient un endophénotype des TB, nous avons mesuré les volumes mésiotemporaux chez des proches jeunes affectés ou non de patients avec TB (méthode de population à risque élevé).
Méthode : Les participants à risque élevé (âgés de 15 à 30 ans) ont été recrutés dans des familles affectées de façon multiple par les TB. Ils comprenaient 20 enfants affectés et 26 enfants non affectés de parents souffrant de troubles bipolaires primaires, jumelés selon l'âge et le sexe, et 31 sujets témoins sans antécédents personnels ou familiaux de troubles psychiatriques. Les volumes des amygdales et de l'hippocampe ont été mesurés sur un appareil 1,5 Tesla de résonance magnétique fournissant des images tridimensionnelles anatomiques, analysées à l'aide des méthodes standards.
Résultats : Nous avons observé des volumes comparables des amygdales et de l'hippocampe chez les proches atients non affectés, affectés à risque élevé et chez les sujets témoins. L'exclusion de 6 proches médicamentés n'a pas changé les résultats. Il n'y avait pas de différences entre les participants ayant des antécédents familiaux de TB I, comparés aux participants ayant des antécédents familiaux de TB II, ou entre les sujets ayant des antécédents familiaux de TB avec symptômes psychotiques, comparés aux sujets ayant des antécédents familiaux de TB sans symptômes psychotiques.
Conclusions :
Les anomalies des volumes des amygdales et de l'hippocampe étaient absentes chez les proches non affectés et affectés de patients avec TB et ne satisfaisaient donc pas aux critères d'un endophénotype.
